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Abstract
Background: To evaluate the sensitivity, specificity and predictive values of fractional exhaled nitric oxide
(FENO) for the diagnosis of asthma in general practice.
Methods: Prospective diagnostic study with 160 patients attending 10 general practices for the first time
with complaints suspicious of obstructive airway disease (OAD). Patients were referred to a lung function
laboratory for diagnostic investigation. The index test was FENO measured with a portable FENO analyser
based on electrochemical sensor. The reference standard was the Tiffeneau ratio (FEV1/VC) as received
by spirometric manoeuvre and/or results of bronchial provocation. Bronchial provocation with
methacholine was performed to determine bronchial hyper-responsiveness (BHR) in the event of
inconclusive spirometric results.
Results: 88 (55%) were female; their average age was 43.9 years. 75 (46.9%) patients had asthma, 25
(15.6%) had COPD, 8 (5.0%) had an overlap of COPD and asthma, and 52 (32.5%) had no OAD. At a cut-
off level of 46 parts per billion (ppb) (n = 30; 18.8%), sensitivity was 32% (95%CI 23–43%), specificity 93%
(95%CI 85–97%), positive predictive value (PPV) 80% (95%CI 63–91%), negative predictive value (NPV)
61% (95%CI 52–69%) when compared with a 20% fall in FEV1 from the baseline value (PC20) after inhaling
methacholine concentration  16 mg/ml. At 76 ppb (n = 11; 6.9%) specificity was 100% (95%CI 96–100%)
and PPV was 100% (95%CI 72–100). At a cut-off level of 12 ppb (n = 34; 21.3%), sensitivity was 90% (95%CI
79–95%), specificity 25% (95%CI 17–34%), PPV 40% (95%CI 32–50), NPV 81% (95%CI 64–91%) when
compared with a 20% fall of FEV1 after inhaling methacholine concentration  4 mg/ml. Three patients with
unsuspicious spirometric results have to be tested with FENO to save one bronchial provocation test.
Conclusion: Asthma could be ruled in with FENO > 46 ppb. Mild and moderate to severe asthma could
be ruled out with FENO  12 ppb. FENO measurement with an electrochemical sensor might be
reasonable with respect to the time consuming procedure of bronchial provocation, which carries also
some risk of severe bronchospasm. Further research is necessary to evaluate the effectiveness of this dual
diagnostic strategy. The number needed to diagnose might be improved when the diagnostic precision
could be enhanced by future technical developments.
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Introduction
Asthma is a common chronic disease with a high preva-
lence of approx. 5% in industrialized nations. It is charac-
terised by an inflammation process which induces
bronchial hyper-responsiveness and usually reversible air-
way obstruction [1]. General practitioners have a key role
in detecting the disease, as in most times patients initially
come to them with complaints which are suspicious of
asthma. Spirometric investigation is seen as being a gold
standard for diagnosing obstructive airway disease (OAD)
[2]. Efficacy of spirometry in diagnosing severe asthma
has already been demonstrated [3]. In mild asthma in par-
ticular, an airway obstruction is often not present, thus
leading to diagnostic uncertainty. Serial peak-flow meas-
urement or bronchial provocation is recommended in
international guidelines for these cases [2]. However, the
low diagnostic value of peak-flow variability has already
been demonstrated [4,5]; and bronchial provocation thus
remains as a gold standard for determining bronchial
hyper-responsiveness [6]. Therefore in Germany, patients
with complaints suspicious for OAD are referred to a
pneumologist for bronchial provocation, if they have
inconclusive spirometric results in general practice. Bron-
chial provocation is indeed time consuming, costly, only
available in specialised centres, and carries a small risk of
inducing severe bronchospasm [7].
A promising non-invasive and easily available method for
diagnosing asthma seems to be the measurement of frac-
tional exhaled nitric oxide (FENO), and increased FENO
concentrations have been found in asthmatic patients
including those with mild disease [8,9]. Increased FENO
is also found in other inflammatory disorders including
sinus disease [10] and viral upper respiratory tract infec-
tion [11], but not in patients suffering from chronic
obstructive pulmonary disease (COPD) [12]; and a high
correlation between FENO and conventional tests for
diagnosing asthma was demonstrated [13]. However, test
characteristics derived from hospital studies are of limited
value in primary care due to the lower incidence and
smaller extent of the particular diseases found there [14].
Dupont et al. attempted to evaluate the diagnostic accu-
racy of FENO for primary care patients [15]. They found a
specificity of 90% and a positive predictive value of > 90%
of FENO in patients referred from general practice to an
asthma outpatient clinic. Berkman et al. found a sensitiv-
ity of 82.5% and specificity of 88.9% in primary care
patients [16]. In both trials a chemoluminescence ana-
lyser was used. However, the use of this tool has until now
been confined to secondary care because of the expense
and physical size of the equipments required to undertake
the measurement. A portable hand-held device with an
electrochemical sensor (NioxMino®) was introduced
recently, which was suggested to have a clinically accepta-
ble agreement with a chemoluminescence device (Niox®)
[17]. The NioxMino® was also evaluated by Menzies et al.
[18], who found likewise a high correlation between
NioxMino® and Niox®. Indeed this instrument was tested
in patients with previously established diagnoses which
could lead to distorted estimation [19], and the predictive
values in relation to different cut-off values were not
determined.
To close this gap, the aim of this study was to investigate
the sensitivity, specificity and predictive values including
the determination of an ideal cut-off value of a portable
FENO analyser (NioxMino®) for diagnosing asthma in pri-
mary care patients. Besides, we wanted to assess the
impact of FENO measurement to reduce referrals from
primary care for bronchial provocation testing.
Methods
Design and Sample
This prospective diagnostic study was performed between
February 2006 and June 2007 with fourteen general prac-
titioners (GPs) working in ten German general practices.
160 patients presenting to their GP for the first time with
complaints suggestive of obstructive airway disease
(OAD) were consecutively included. Inclusion criteria
were the presentation of symptoms such as dyspnoea,
coughing or expectoration for more than two months,
thus leading to clinical suspicion of obstructive or restric-
tive airway disease as most important differential diag-
noses ('indicated population'). GPs were advised to
exclude patients with respiratory tract infections preced-
ing the evaluation by 6 weeks. The medical history was
recorded using a structured questionnaire (Table 1). The
atopic status and rhinitis severity were not evaluated in
detail due to the primary care setting of the study. Spirom-
etry was performed in general practice for initial estima-
tion of airway obstruction. Airway obstruction was
diagnosed when FEV1/VC  0.70 and/or FEV1 < 80% [2].
Lung function reference values corrected for sex, age, and
height were used [20]. After initial estimation by their GP
patients were sent to the lung function laboratory of the
University Medical Hospital. If immediate treatment was
necessary due to severe airway obstruction, it was initiated
by the GP. Patients were instructed not to use any bron-
chodilator or inhaled steroid and stop smoking and
drinking coffee twelve hours before visiting the lung func-
tion laboratory.
Patients with previously established diagnosis of OAD
were excluded. Other exclusion criteria related to well
known contra-indications for bronchodilator reversibility
testing or bronchial provocation, namely untreated hyper-
thyreosis, unstable coronary artery disease, and cardiac
arrhythmia. Pregnancy also led to exclusion. The study
was approved by the Medical Ethics Committee of theRespiratory Research 2009, 10:15 http://respiratory-research.com/content/10/1/15
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University of Heidelberg. Patients gave written informed
consent.
Based on the pilot study [21], we estimated the pre-test
probability of asthma as 45%. In previous trials with a
chemoluminescence analyser, sensitivity varied from
82.5% [16] to 69% [15], and specificity from 88 [16] to
80% or respectively 90% [15] (depends on the choice of
cut-off point). We conservatively estimated a sensitivity of
69% and a specificity of 80%. Power calculation based on
these estimations showed that we had to include at least
149 patients to determine PPV with a 95%CI of ± 10%
[22].
Index Test: FENO – Measurement
All patients underwent the measurement of FENO using
the NioxMino® analyzer at a mouth flow rate of 50 mL/s
over ten seconds and a pressure of 10 cm H2O as per
guideline recommendation [23]. A feedback signal of
exhalation pressure and exhalation flow was used to con-
trol the low flow rate. This procedure was performed at
the lung function laboratory of the University Medical
Hospital before investigation with bodyplethysmography
and bronchial provocation, as forced inspiratory and
expiratory manoeuvres could lead to distorted FENO
results. The manufacturer Aerocrine® recommended an
elevated level at FENO > 20 ppb (as intermediate level)
and a level of FENO > 35 ppb as a clear indication for an
eosinophilic inflammation in adult patients which is sup-
ported by several studies [13,18,24,25].
Reference Test: Bodyplethysmography and Bronchial 
Provocation
The respiratory manoeuvres were performed according to
standard protocols [26]. Lung function reference values
corrected for sex, age, and height were used [20]. Patients
with FEV1 < 80% of predicted received a bronchodilation
test with an additional performance of whole body
plethysmography (WBP) 20 minutes after inhaling salb-
utamol. An obstructive airway disease was diagnosed if
FEV1/VC  0.70. The obstruction was classified as COPD,
if the bronchodilation response FEV1 after salbutamol
was < 12% as compared to baseline and below 200 ml [2]
(Figure 1). The obstruction was classified as asthma when
FEV1was  12% as compared to baseline and at least 200
ml and lung volumes returned to predicted normal range.
An incomplete bronchodilator response was stated if the
bronchodilation response was  12% as compared to
baseline and at least 200 ml and lung volumes remained
below predicted. We labeled this group 'overlap' as it
shows spirometric properties of both, asthma and COPD
[27-29]. If there was no bronchial obstruction, bronchial
provocation was performed to determine bronchial
hyper-responsiveness (BHR). Bronchial provocation is
considered to be the best method for diagnosing asthma
[6], although there is conflicting evidence [30] probably
arising from variations in the populations studied, as the
diagnostic value increases with pre-test probability of the
disease [31]. Professional lung function technicians meas-
ured bronchial hyper-responsiveness to methacholine
according to the ATS guidelines [7]. An "asthma" diagno-
sis was made when there was a 20% fall in FEV1 from the
baseline value (PC20) after inhaling methacholine step-
Table 1: Characteristics of the study population. Values indicate the number (proportion) or mean (SD); OAD = Obstructive Airway 









n 75 (46.9) 25 (15.6) 8 (5.0) 52 (32.5)
Female 44 (58.7) 15 (60.0) 4 (50.0) 22 (42.3)
FENO (mean in parts per billion [sd]) 42.6 [47.9] 16.2 [11.1] 20.4 [18.6] 24.7 [16.0]
Age (mean in years [sd]) 38.7 [15.1] 55.7 [11.9] 63.5 [10.5] 42.8 [15.8]
FEV1 (mean of absolute values in litre [sd]) 3.43 [0.76] 2.12 [0.73] 1.93 [0.55] 3.52 [0.92]
FEV1 (mean of % of predicted [sd]) 100 [12.2]  67.8 [18.5] 68.8 [18.4]  107.4 [12.8] 
FEV1/VC (mean of % [sd]) 78.45 [7.02] 59.7 [8.4]  58.2 [7.6] 82.1 [5.8]
Do you ever suffer from shortness of breath? (yes) 48 (64.0) 20 (80.0) 6 (75.0) 27 (51.9)
Do you ever suffered from wheezing in your chest? (yes) 39 (52.0) 15 (60.0) 3 (37.5) 19 (36.5)
Do you often suffer from a cough? (yes) 32 (42.7) 15 (60.0) 4 (50.0) 40 (76.9)
Do you often suffer from expectoration? (yes) 19 (25.3) 10 (40.0) 3 (37.5) 19 (36.5)
Have you ever woken up with a feeling of tightness in your chest? (yes) 19 (25.3) 4 (16.0) 3 (37.5) 8 (15.4)
Have you ever been woken up by an attack of shortness of breath? (yes) 21 (28.0) 3 (12.0) 2 (25.0) 9 (17.3)
Have you ever had an asthma attack? (yes) 7 (9.3) 1 (4.0) 0 (0) 1 (1.9)
Do you suffer from any nasal allergies? (yes) 40 (53.3) 7 (28.0) 1 (12.5) 23 (44.2)
Do you smoke or did you previously smoke? (yes) 30 (40.0) 24 (96.0) 8 (100) 24 (46.2)
How much do/did you smoke? (mean in pack year ([sd]) 6.7 [13.3] 35.6 [20.6] 26.5 [17.4] 5.0 [11.1]Respiratory Research 2009, 10:15 http://respiratory-research.com/content/10/1/15
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wise until the maximum concentration (16 mg/mL) [7].
The pneumologist was blinded to the FENO results and
made the diagnostic decision only on basis of medical his-
tory, physical examination, bodyplethysmography and
bronchial provocation results.
Data Analysis
Baseline data is presented descriptively. Two-by-two con-
tingency tables of FENO values vs. asthma diagnoses (yes
or no) were prepared using different levels of FENO as cut-
off point. Sensitivity, specificity and predictive values were
calculated for each cut-off point. A receiver operating
characteristic (ROC) curve was plotted, which allowed a
graphical representation of sensitivity and specificity. The
cut-off points were analysed with respect to different pre-
dictive values. One method of identification is through
the highest sum of sensitivity and specificity. Another
opportunity is choosing at the highest PPV when NPV was
acceptable (or vice versa) at the same cut-off point. Both
methods were used. The data was analysed with SPSS 15.0
for Windows. 95% confidence intervals were calculated
using Wilson's method [32] with the statistical package
CIA (Confidence Interval Analysis) [33]. Positive likeli-
hood ratios (LR+) were calculated to receive the ratio of
abnormal finding in ill and healthy subjects. Negative
likelihood ratios (LR-) were calculated for the ratio of nor-
mal findings in ill and healthy subjects. 95% confidence
intervals were derived from the log method [22]. An
explanation of how to interpret PPV and NPV is given in
figure 2.
The differentiation between asthma, COPD and overlap is
a complex problem and sometimes requires repeated
measurements after trials of medication. In particular, a
negative or incomplete bronchodilation test might be due
to a fixed airway obstruction in asthma and not due to
COPD. As long term follow up was not possible for organ-
isational reasons, we performed sensitivity analyses with
Diagnostic decision making with the reference standard (COPD = Chronic Obstructive Pulmonary Disease, OAD = obstruc- tive airway disease) Figure 1
Diagnostic decision making with the reference standard (COPD = Chronic Obstructive Pulmonary Disease, 
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ROC analyses when currently non-smoking patients with
less than a five pack year history of nicotine use (initially
labelled as COPD or overlap) were classified as asthma
patients. Additional sensitivity analyses to control for con-
founders were performed with exclusion of actually smok-
ing patients [34] and patients using inhaled steroids [35].
Subanalysis was performed for patients with allergic rhin-
itis in medical history [36].
In particular the diagnostic decision making based on
methacholine challenge testing is difficult as there is no
full agreement about the cut-off value to be used [30]. The
ATS guidelines suggest a cut-off at 16 mg/mL [7], which
was also used by Kostikas et al. to evaluate FENO in young
adults during pollen season [37]. Berkman determined a
cut-off of 3 mg/mL [16], and 8 mg/mL is also commonly
used [4,6,15]. Due to this lack of agreement, we calculated
cut-off values of FENO with respect to different concentra-
tions of methacholine during bronchial provocation test-
ing, categorised into borderline BHR (4 mg/mL <
methacholine concentration  16 mg/mL), mild BHR (1
mg/mL < methacholine concentration  4 mg/mL), and
moderate to severe BHR (methacholine concentration < 1
mg/mL) following the ATS guideline [7].
Results
Study Population
A total of 160 patients participated in the study (88 [55%]
female). The recruitment rate was 76%. Patients mostly
complained of dyspnea (63.1%), coughing (56.9%),
wheezing (45.5%) and allergic rhinitis (44.4%) (Table 1).
Seven (4.4%) patients received inhaled steroids (200 to
400 g budesonide per day) from their GP. Two patients
received only short acting -agonists. Four received long
acting  -agonists in addition to inhaled steroids. The
duration of treatment was not longer than one or tow
weeks as the patients were referred to the lung function
laboratory at once. Patients were advised by their GP not
Calculation example for the relation between pretest probability, sensitivity, specificity, PPV and NPV Figure 2
Calculation example for the relation between pretest probability, sensitivity, specificity, PPV and NPV.Respiratory Research 2009, 10:15 http://respiratory-research.com/content/10/1/15
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to use inhaled medication for twelve hours before lung
function testing. According to the results of WBP and
bronchial provocation, 75 (46.9%) patients had asthma,
25 (15.6%) had COPD, 8 (5.0%) had an incomplete
bronchodilator response (overlap), and 52 (32.5%)
patients had no OAD. 36% showed signs of airway
obstruction in spirometry in general practice, and 31%
showed airway obstruction in the lung function labora-
tory. Most patients suffered from mild to moderate
asthma or COPD, respectively. FEV1 and VC values are
given in table 1. Three patients had FEV1 < 80% and FEV1/
VC > 0.70; two had asthma (non-smokers), one had
COPD (smoker). Patients with asthma had the highest
average of FENO levels. Patients with COPD and with an
overlap of COPD and asthma were significantly older and
had more pack years of smoking than asthma patients (p
< 0.001 for each difference; t-Test). At the lung function
laboratory the diagnosis of asthma was made in 61 cases
with bronchial provocation. According to the ATS guide-
line categories [7], 17 patients had borderline BHR, 29
had mild BHR and 15 had moderate to severe BHR. Only
14 patients were identified solely on the basis of bron-
chodilator reversibility testing.
Estimates of the Diagnostic Accuracy of FENO
The highest FENO measures are attributed to the diagno-
sis asthma, as the box-plot illustrates (Figure 3). The area
under the curve was 0.645 (95%CI 0.559–0.731; p =
0.002) if compared with a 20% fall of FEV1 after inhaling
methacholine concentration  16 mg/mL and/or positive
bronchodilator response. The results of the ROC analysis
are illustrated in figure 4. The highest sum of sensitivity
and specificity was given at cut-off 46 ppb (Table 2). The
pre-test probability of 'having asthma' (46.9%) was
enhanced up to a PPV of 80%. LR+ was highest at this cut-
off point (Table 3). 30 (19.2%) patients had a FENO > 46
ppb. Therefore, five patients had to be diagnosed with the
FENO analyser to save one bronchial provocation. There
were no notable differences when patients with inhaled
steroids were excluded from calculation, PPV remained
80%.
At the cut-off point 76 ppb every patient would be cor-
rectly diagnosed as having asthma. 11 (6.9%) asthma
patients had a FENO > 76 ppb. Therefore, nearly fifteen
patients had to be diagnosed with the FENO analyser to
save one bronchial provocation. It was not possible to
exclude asthma (diagnosed with methacholine concentra-
tion  16 mg/mL) with this FENO cut-off value, as the pre-
test probability of 'not having asthma' was within the 95%
confidence interval of NPV. PPV was only 63% (95%CI
47–77) at the cut-off value > 35 ppb. At the cut-off point
12 ppb, which was established by Menzies et al. [18], we
received very low PPV.
In a second step, we analyzed if FENO helped to identify
asthmatics among all subjects with unsuspicious spiro-
metric results (n = 101; not in table). 49 of these patients
had asthma (pre-test probability 48.5%). The optimal cut-
off with highest sum of sensitivity and specificity was at 46
ppb again. The sensitivity of FENO > 46 ppb for these
patients with unsuspicious spirometry was 35% (95%CI
23–49%), specificity was 90% (95%CI 79–96%), PPV
77% (95%CI 47–90%) and NPV 59% (95%CI 49–70%).
24 (23.8%) patients had a FENO > 46 ppb. Therefore, four
patients with unsuspicious spirometric results had to be
diagnosed with the FENO analyser to save one bronchial
provocation.
Sensitivity analyses
Ten patients with COPD and three patients with overlap
had already stopped smoking several years before the
examination. Four of them had accumulated one to three
pack years. The diagnoses of these four patients changed
into asthma. The other patients had accumulated ten to
80 pack years (mean 37.2 ± 26.3) and were consequently
labelled as COPD further on. If these diagnostic changes
were taken into account, the ideal cut-off level would
remain at 46 ppb. In this case, the sensitivity was 30%
(95%CI 21–41%), specificity 93% (95%CI 85–97%),
positive predictive value (PPV) 80% (95%CI 63–91), NPV
57% (95%CI 49–66%). At 83 ppb specificity was 100%
(95%CI 96–100%) and PPV was 100% (95%CI 72–100)
(not in table).
There was a slight change of the results when the data were
analyzed solely with non-smokers (n = 110). Again, the
ideal cut-off remained at 46 ppb with sensitivity 34%
(95%CI 23–46%) and specificity 94% (95%CI 83–98%).
PPV increased up to 88% (95%CI 69–96%) and NPV was
52% (95%CI 42–63%). At 65 ppb specificity was 100%
(95%CI 93–100%) and PPV was 100% (95%CI 77–
100%) (not in table). In patients reporting allergic rhinitis
(n = 47), test accuracy of FENO increased slightly at FENO
> 46 ppb. Sensitivity was 45% (95% 31–60), specificity
90% (95%CI 75–97), PPV 86% (95%CI 65–95), NPV
56% (95%CI 42–69).
If only patients with mild, moderate to severe BHR, and/
or positive bronchodilator response were accepted for the
diagnosis asthma, the best NPV was found at ENO  12
ppb. NPV was 81% (95% CI 64–91); and LR- was lowest
at this cut-off point (Table 3). 34 patients had FENO  12
ppb. Therefore, five patients have to be diagnosed to save
one bronchial provocation for excluding asthma. There
was no improvement of test accuracy in patients with
unsuspicious spirometric results (n = 101; not in table).
The best cut-off was at 12 ppb again. Sensitivity was 89%
(95%CI 75–96), specificity was 19% (95%CI 11–30),
PPV was 39% (95%CI 29–50), NPV was 75 (95%CI 51–Respiratory Research 2009, 10:15 http://respiratory-research.com/content/10/1/15
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90) (not in table). 16 (15.8%) had a FENO  12 ppb. NPV
increased up to 82% (95%CI 64–92) when patients with
inhaled steroids were excluded from calculation.
Discussion
To our knowledge, this is the first study evaluating the
diagnostic accuracy of a portable FENO analyser based on
an electrochemical sensor in a prospective design in pri-
mary care setting. At the highest sum of sensitivity and
specificity, we found a reasonable cut-off point at > 46
ppb which allows diagnosing asthma with a PPV of 80%.
At a cut-off point > 76 ppb, specificity and PPV was 100%,
which means asthma can be ruled in with the highest cer-
tainty. Mild and moderate to severe asthma can be
excluded with NPV 81%, when FENO  12 ppb.
Due to these findings, FENO measurement might have an
impact on the diagnostic management of patients. Five
patients have to be evaluated with FENO to save one
bronchial provocation test for ruling in asthma, and five
patients have to be evaluated to exclude mild and moder-
ate to severe asthma. The number could be decreased for
ruling in when used in patients with unsuspicious spiro-
metric results. In that case four patients need to be evalu-
ated with NioxMino® to save one bronchial provocation.
In patients with unsuspicious spirometric results (n =
Box-Plot of FENO measures in relation to the diagnoses of the reference standard (body plethysmography and bronchial prov- ocation) Figure 3
Box-Plot of FENO measures in relation to the diagnoses of the reference standard (body plethysmography and 
bronchial provocation). (Black circle) mild outlier between 1.5th and 3rd interquartile range. (Black asterisk) extreme outlier 
more than 3rd interquartile range.Respiratory Research 2009, 10:15 http://respiratory-research.com/content/10/1/15
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101), 16 patients had FENO  12 ppb and 24 had FENO
> 46 ppb. Therefore, altogether three patients have to be
tested with FENO to save one bronchial provocation. In
Germany, investigation by a pneumologist including
bronchial provocation would costs around 110n which
need to be compared with the costs of three FENO meas-
urements (102n; 34 n per measurement [38]). Thus it
seems reasonable to perform spirometric investigation at
first in patients suspected to suffer from asthma. FENO
measurement could be performed if spirometry shows no
signs of airway obstruction, in particular as bronchial
provocation is time consuming, carries a small risk [7]
and cannot be performed in general practices. Therapy
with inhaled steroids should be initiated when FENO > 46
ppb due to the already demonstrated dose-response rela-
tionship [35,39]. Mild and moderate to severe asthma is
ROC curve for measurement of FENO in the diagnosis of asthma (AUC = 0.645; 95%CI 0.559–0.731) Figure 4
ROC curve for measurement of FENO in the diagnosis of asthma (AUC = 0.645; 95%CI 0.559–0.731).Respiratory Research 2009, 10:15 http://respiratory-research.com/content/10/1/15
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excluded when FENO  12 ppb. Referral for bronchial
provocation seems to be indicated for intermediate values
when 12 ppb < FENO  46 ppb.
This dual strategy for primary care patients was already
used in an observational study with 55 patients by Hewitt
et al. [40]. In this study FENO cut-offs at 20 ppb and 35
ppb were used, which were established by reproducibility
measurements with the Niox® chemoluminescence ana-
lyser [24]. This is in contrast to our range of indifferent
results from 12 to 46 ppb. Our results might be explaina-
ble in relation to a study by Alving et al. who evaluated the
agreement of NioxMino® and Niox® [17]. They found the
limits of 95% confidence interval of agreement were -9.8
and 8.0 ppb. They stated that from a clinical point of view,
accuracy is more important in a FENO range close to a cut-
off between healthy and disease (20–35 ppb). The sum of
the upper limit of the 95% CI (8 ppb) and 35 ppb is close
to our best cut-off point (46 ppb) to rule in asthma; and
the difference of the 95%CI (-9.8 ppb) and 20 ppb is close
to our best cut-off point (12 ppb) to rule out asthma.
Therefore, our findings might be due to a discrete impre-
cision of the electrochemical sensor. However, also with a
20 ppb cut-off point exclusion of asthma would be possi-
ble, with lower NPV. Beside that, our results indicate that
a more sure positive diagnosis of asthma might be pro-
vided with FENO at 46 ppb, as stated above. Further
research with long term follow-up would be necessary to
evaluate the effectiveness of the dual diagnostic strategy
with different FENO cut-off points.
Our study has some limitations, the most important one
being related to the conflicting evidence about the ideal
cut-off of for bronchial provocation testing with metha-
choline, which might be due to variation in the popula-
tions studied and the severity of disease [30,31]. The lack
of consensus is also reflected by the use of different cut-off
values in different diagnostic studies [4,6,15,16], which is
in contrast to the cut-off at 16 mg/mL as suggested by the
ATS guideline [7]. We took this limitation into account by
performing sensitivity analyses with exclusion of patients
with borderline BHR. Despite the lack of an ideal 'gold
Table 2: Sensitivity (sens), specificity (spec), positive predictive value (PPV) and negative predictive value (NPV) at different cut-off 
points (n = 160); unit of FENO is parts per billion









Borderline BHR > 12 85 (76–92) 24 (16–34) 50 (41–58) 65 (47–79) 126
mild BHR > 20 64 (53–74) 58 (47–77) 57 (47–67) 65 (53–74) 82
moderate to severe BHR > 35 32 (25–42) 84 (74–90) 63 (47–77) 58 (49–67) 38
positive bronchodilator reversibility  > 46 32 (23–43) 93 (85–97) 80 (63–91) 61 (52–69) 30
(n = 75)* > 76 13 (7–23) 100 (96–100) 100 (72–100) 57 (49–65) 11
Mild BHR > 12 90 (79–95) 25 (17–34) 40 (32–50) 81 (64–91) 126
moderate to severe BHR > 20 67 (54–78) 62 (52–71) 50 (39–61) 77 (67–85) 82
positive bronchodilator reversibility > 35 36 (25–49) 83 (75–89) 55 (40–70) 70 (61–77) 38
(n = 58)§ > 46 36 (25–49) 91 (84–95) 70 (52–83) 72 (63–79) 30
> 76 17 (10–29) 100 (96–100) 100 (72–100) 68 (60–75) 11
*prevalence of asthma = 46.9%, prevalence of 'no asthma' = 53.1%
§ prevalence of asthma = 36,3%, prevalence of 'no asthma' = 63.7%
Table 3: Likelihood ratio at different cut-off points (n = 160); unit of FENO is parts per billion; LR+ is positive likelihood ratio, LR- is 
negative likelihood ratio
Asthma diagnoses FENO LR+ (95%CI) LR-(95%CI)
Borderline BHR, mild BHR, moderate to severe BHR, positive bronchodilator reversibility (n = 75) > 12 1.12 (0.96–1.30) 0.62 (0.32–1.22)
> 20 1.55 (1.12–2.14) 0.65 (0.47–0.91)
> 35 1.94 (1.09–3.48) 0.81 (0.68–0.98)
> 46 4.53 (1.96–10.49) 0.73 (0.62–0.86)
> 76 not calculable not calculable
Mild BHR, moderate to severe BHR, positive bronchodilator reversibility (n = 58) > 12 1.19 (1.03–1.37) 0.42 (0.18–0.97)
> 20 1.76 (1.30–2.39) 0.53 (0.36–0.79)
> 35 2.17 (1.25–3.77) 0.77 (0.62–0.95)
> 46 4.10 (2.02–8.36) 0.70 (0.57–0.86)
> 76 not calculable not calculableRespiratory Research 2009, 10:15 http://respiratory-research.com/content/10/1/15
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standard', our finding implicates that it is possible in gen-
eral practice to rule out mild and moderate to severe
asthma with FENO measurement. Borderline BHR could
not be excluded indeed.
It has been shown that the current clinical guideline rec-
ommended FEV1/VC cut-off at 0.70 might lead to sub-
stantial over-diagnosis of COPD [41]. However, most
patients identified as COPD were heavy smokers (21 of 25
with at least ten pack years), and patients with asthma had
positive bronchodilation response or positive bronchial
provocation result. That makes a false diagnostics improb-
able from a clinical point of view. Another point of discus-
sion is the correct classification of the eight patients with
only incomplete bronchodilator response. The best way
for differentiation would have been a long term follow-up
with trials of inhaled steroids, which was not possible
within the study design. Beside that, bronchial provoca-
tion in all patients might have been helpful for further dif-
ferentiation. However, this was not allowed by the Ethics
Committee due to the risk of severe bronchial spasm.
Based on medical history and spirometry investigation,
five patients were very similar to COPD (all were heavy
smokers) and the remaining three were most probably
asthma patients with fixed airway obstruction. The sensi-
tivity analyses showed that the cut-off point of FENO
remained the same when actually non-smoking patients
initially labelled as COPD or overlap were classified as
asthma patients with fixed airway obstruction. This might
attenuate the potential limitation, in particular as this dif-
ficult diagnostic group was small.
We included all patients referred by the GPs, even patients
with current high tobacco use. It has been shown that
tobacco smoke decreases exhaled NO [34], which could
lead to false negative diagnoses. However, the exclusion of
smokers from our analyses showed similar results. This
might be due to the lower tobacco use of the asthma
patients in our sample, thus accompanied by lower rate of
distorted results. Another distortion might be caused by
inclusion of patients with nasal allergies (44.4%), which
could lead to elevated FENO [36]. However, PPV
increased in this group. Another critical point is the posi-
tive correlation of FENO with age and sex [42] which
might lead to reduced diagnostic accuracy [43]. However,
especially in general practice unselected patients appear
with various complaints and various ages which does not
allow pre-selection in using diagnostic devices. Therefore
this can also be seen as strength of the present study since
we tried to evaluate the diagnostic accuracy under clinical
reality in primary care. A solution for enhancing diagnos-
tic accuracy might be found when adjusted norm values
could be established as was postulated by Taylor et al.
[42]. Therefore, in the near future FENO might prove
more useful in terms of accuracy and of cost-effectiveness
in asthma sub-phenotypes, like allergic patients or cough
variant asthma. Another limitation is due to the lower
severity of disease which is typically found in primary care
population. Most patients with asthma were identified
with bronchial provocation. Thus, our results might not
be applicable to subjects with more severe OAD as found
in secondary or tertiary care. It was not possible to specify
the alternate diagnosis of the patients with no OAD,
which is also a typical problem of diagnostic studies in
primary care. It was impossible to perform every investi-
gation (e.g. gastroscopy to determine gastro-oesophageal
reflux; x-ray) until a definite diagnosis could be made.
This would not have been allowed by the Ethics Commit-
tee. However, this limitation does not alter the FENO
results. A final limitation might be that we used only a sin-
gle FENO measurement, whereas the mean of three meas-
urements is recommended by the guidelines [23]. On the
other hand, it was recently stated that one measurement is
about as precise as three measurements [17]; and its also
clinical reality that more than one measurement is too
expensive for routine use in general practice.
Conclusion
FENO measurement with a portable electrochemical ana-
lyzer seems to be effective for ruling in and ruling out
asthma in general practice. Asthma could be ruled in sat-
isfyingly with a cut-off at FENO > 46 ppb. Mild and mod-
erate to severe asthma could be ruled out satisfyingly
using FENO  12 ppb as a cut-off point. In sum, three
patients with unsuspicious spirometric results have to be
tested with FENO to save one bronchial provocation test.
Therefore, FENO measurement might be reasonable as
bronchial provocation is a time consuming procedure and
carries a small risk of severe bronchospasm. Further
research is necessary to evaluate the effectiveness of this
dual diagnostic strategy. The number needed to diagnose
might be improved when the diagnostic precision could
be enhanced by future technical developments.
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